Breaking News

Charles River Acquires CDMO Cognate BioServices

Pays roughly $875 million to significantly expand capabilities in the cell and gene therapy sector.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Laboratories has signed an agreement to acquire Cognate BioServices, a cell and gene therapy contract development and manufacturing organization (CDMO), for approximately $875 million. The deal is expected to close by the end of the first quarter of 2021.   “Cognate BioServices presents a unique opportunity to expand into a high-growth, value-added sector of the CDMO market and enhance our ability to meet our clients’ needs in emerging areas of scientific innovation,” said James C....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters